Current and Emerging Medical Treatments for Uterine Fibroids

Semin Reprod Med. 2017 Nov;35(6):510-522. doi: 10.1055/s-0037-1606302. Epub 2017 Nov 3.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / trends
  • Cost of Illness
  • Drug Approval
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / therapeutic use*
  • Evidence-Based Medicine*
  • Female
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors
  • Gonadotropin-Releasing Hormone / metabolism
  • Hormone Antagonists / adverse effects
  • Hormone Antagonists / therapeutic use
  • Humans
  • Leiomyoma / drug therapy*
  • Leiomyoma / metabolism
  • Leiomyoma / physiopathology
  • Leiomyoma / therapy
  • Leiomyomatosis / drug therapy*
  • Leiomyomatosis / metabolism
  • Leiomyomatosis / physiopathology
  • Leiomyomatosis / therapy
  • Menorrhagia / etiology
  • Menorrhagia / prevention & control
  • Quality of Life
  • Receptors, Progesterone / antagonists & inhibitors
  • Receptors, Progesterone / metabolism
  • United States
  • United States Food and Drug Administration
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / metabolism
  • Uterine Neoplasms / physiopathology
  • Uterine Neoplasms / therapy

Substances

  • Drugs, Investigational
  • Hormone Antagonists
  • Receptors, Progesterone
  • Gonadotropin-Releasing Hormone